Abstract
Aim: The present study was undertaken to replicate the association of candidate genes for anti-TNF response in rheumatoid arthritis. Candidate genes were selected from a recent genome-wide association study on anti-TNF response performed in a population from Denmark. Materials & methods: Genomic DNA was obtained from 315 Spanish rheumatoid arthritis patients having received an anti-TNF agent as their first biological therapy. SNPs from NR2FR2, MAP2K6, CBLN2 and PDE3A-SLCO1C1 candidate loci were genotyped. Results: The PDE3A-SLCO1C1 locus rs3794271 SNP showed a highly significant association with anti-TNF treatment response (p = 1.74 × 10-5). Combining the statistical evidence from the Spanish and Danish rheumatoid arthritis cohorts, the associated rs3794271 SNP reached a genome-wide significance level of association (p = 3.3 × 10-10). Conclusion: The present findings establish the PDE3A-SLCO1C1 locus as a strong genetic marker of anti-TNF therapy response. Original submitted 9 January 2013; Revision submitted 13 March 201. © 2013 Future Medicine Ltd.
Author supplied keywords
Cite
CITATION STYLE
Acosta-Colman, I., Palau, N., Tornero, J., Fernández-Nebro, A., Blanco, F., González-Alvaro, I., … Marsal, S. (2013). GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics, 14(7), 727–734. https://doi.org/10.2217/pgs.13.60
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.